Prevention of cytomegalovirus infection in organ transplant recipients

Transplant Infectious Disease

Volumn 2, Issue 3, 2000, Pages 99-100

  Rubin, R H ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; GANCICLOVIR; PLACEBO; VALACICLOVIR;

CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DOSE TIME EFFECT RELATION; EDITORIAL; HUMAN; HUMAN CELL; HUMAN TISSUE; INFECTION PREVENTION; MULTICENTER STUDY; ORGAN TRANSPLANTATION; PATIENT MONITORING; PRIORITY JOURNAL; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; HUMANS; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; VIRUS REPLICATION;

EID: 0033817535     PISSN: 13982273     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3062.2000.020301.x     Document Type: Editorial

References (7)

1. Infection in organ transplant recipients
2. Preemptive treatment approach to CMV infection in solid organ transplant patients: Relationship between compliance with the guidelines and prevention of CMV morbidity
3. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis
4. Cytomegalovirus infection and cardiac allograft vasculopathy
5. Cytomegalovirus infection-enhanced allograft arteriosclerosis is prevented by DHPG prophylaxis in the rat
6. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation
7. Impact of prophylactic immediate post-transplant ganciclovir on development of transplant atherosclerosis. A post-hoc analysis of a randomized, placebo-controlled study